Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19 - Willems, L.H.; Nagy, M.; ten Cate, H.; Spronk, H.M.H.; Groh, L.A.; Leentjens, J.; Janssen, N.A.F.; Netea, M.G.; Thijssen, D.H.J.; Hannink, G.; van Petersen, A.S.; Warlé, M.C. (Thrombosis research, 2022)
Keywords: Blood coagulation; Cohort Studies; COVID-19; Endothelial cells; Endothelin-1; Hematology, Oncology, and Palliative Medicine; Humans; Inflammation; Pandemics; SARS-CoV-2; Blood coagulation; IL; CI; F; TAT; PKa; Inflammation; PSM; SMD; Endothelial cells; COVID-19; VWF:Ag; SD; RD; SARS-CoV-2; ET-1; CAR; NLRP3; α1AT; C1inh; PCR; ELISA; WHO; Interleukin; Standard Deviation; Standardized Mean Differences; C1 esterase inhibitor; Coronavirus Disease 2019; Factor; Polymerase Chain Reaction; World Health Organization; Enzyme-Linked Immunosorbent Assay; Risk Difference; Severe Acute Respiratory Syndrome Coronavirus 2; Kallikrein; Propensity Score Matching; Thrombin:Antithrombin; Von Willebrand Factor:Antigen; Carotid Artery Reactivity; Nod-like receptor family pyrin domain containing 3; alpha 1 antitrypsin; Confidence Interval; Endothelin-1